Clinical trials
Obstructive Hypertrophic Cardiomyopathy clinical trials
Below are recruiting obstructive hypertrophic cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Anchorage, AlaskaAges 18 years+ - NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04265040Recruiting
Heart muscle disease registry for non-ischemic conditions
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
Heidelberg, Baden-WurttembergAges 18–80 - NCT05332691Recruiting
Beating-heart septal myectomy for thick-heart blockage
This trial studies surgery that removes part of the thick heart muscle while the heart is still beating to relieve a blockage that makes blood leaving the heart harder. It may help people with hypertrophic obstructive cardiomyopathy whose symptoms persist despite medication.
Wuhan, HubeiAges 8 years+ - NCT05569382RecruitingPhase 4
Testing bisoprolol and verapamil in hypertrophic heart disease
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
Aarhus NAges 18 years+ - NCT05818605Recruiting
Exercise training for people with hypertrophic heart muscle
This study tests whether a 24-week exercise program can improve exercise tolerance in people with hypertrophic cardiomyopathy (a thickened heart muscle). You may be asked to use phone-based tools and complete surveys during training.
San Francisco, CaliforniaAges 18–80 - NCT06146660Recruiting
Mavacamten safety study in Korean patients with oHCM
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
SeoulAges 19 years+ - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
La Jolla, CaliforniaAges 18 years+ - NCT07077005Recruiting
Can Mavacamten Help You Exercise More?
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Munich, BavariaAges 18–99 - NCT07150299Recruiting
How heart medications affect blood flow in hypertrophic cardiomyopathy
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
ViennaAges 18 years+ - NCT07361289Recruiting
Mavacamten for obstructive hypertrophic cardiomyopathy in China
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+ - NCT07383025Recruiting
Mavacamten safety study for heart muscle disease in Japan
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
TokyoAges 18 years+ - NCT07557498Recruiting
Mavacamten Outcomes and Experiences in Heart Muscle Disease
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Bollington, MacclesfieldAges 18 years+ - NCT07595354Recruiting
Safe Exercise Plan for Young People at Risk of Heart Disease
This study helps children and teens who may be at risk for a heart condition called HCM learn safe ways to exercise. Researchers will create a personalized exercise plan and check in regularly to see how it goes.
LiverpoolAges 10–18 - NCT07600177RecruitingPhase 4
Switching Heart Medicines: Mavacamten to Aficamten
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Kansas City, MissouriAges 18–90 - NCT06977646Enrolling by invitation
Heart surgery for apical hypertrophic cardiomyopathy without valve pressure
This study looks at people who have had surgery to reshape the left side of the heart for a specific type of thickened heart muscle (apical hypertrophic cardiomyopathy). It helps doctors understand how well this surgery works in patients without a large pressure difference across the heart valve.
Moscow, MoscowAges 15 years+ - NCT06683872Enrolling by invitation
CT heart modeling for hypertrophic obstructive cardiomyopathy
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
Hangzhou, ZhejiangAges 18–70 - NCT05100420Enrolling by invitation
HCM registry and DNA/imaging data collection study
This study collects health records, heart ultrasound (echo), MRI images, and optional DNA testing for people with hypertrophic cardiomyopathy (HCM). It aims to build a large database to better understand HCM and support future research and care.
Edmonton, AlbertaAges Any age - NCT06580717RecruitingPhase 4
Testing empagliflozin for heart stiffness in hypertrophic cardiomyopathy
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
SeoulAges 19–80 - NCT07120776Recruiting
PET scan study for chest pain in hypertrophic cardiomyopathy
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
ManchesterAges 18 years+ - NCT07541833Recruiting
Mavacamten Treatment Patterns in Obstructive Heart Thickening
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Minato-ku, TokyoAges 18 years+
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for obstructive hypertrophic cardiomyopathy?
- Yes. Clin2 currently lists 32 recruiting obstructive hypertrophic cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a obstructive hypertrophic cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a obstructive hypertrophic cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.